-
Je něco špatně v tomto záznamu ?
Analysis of incidence and prevalence of cardiovascular risk factors and evaluation of their control in epidemiological survey in the Czech Republic
Z. Chmelík, M. Vaclová, V. Lánská, J. Laštůvka, M. Vrablík
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články
Digitální knihovna NLK
Zdroj
NLK
Free Medical Journals
od 2004
ProQuest Central
od 2009-03-01 do Před 6 měsíci
Medline Complete (EBSCOhost)
od 2006-03-01 do Před 6 měsíci
Nursing & Allied Health Database (ProQuest)
od 2009-03-01 do Před 6 měsíci
Health & Medicine (ProQuest)
od 2009-03-01 do Před 6 měsíci
Public Health Database (ProQuest)
od 2009-03-01 do Před 6 měsíci
ROAD: Directory of Open Access Scholarly Resources
od 1993
PubMed
32592555
DOI
10.21101/cejph.a5730
Knihovny.cz E-zdroje
- MeSH
- antihypertenziva terapeutické užití MeSH
- diabetes mellitus 2. typu farmakoterapie epidemiologie MeSH
- dospělí MeSH
- dyslipidemie farmakoterapie epidemiologie MeSH
- hypertenze farmakoterapie epidemiologie MeSH
- incidence MeSH
- inhibitory ACE terapeutické užití MeSH
- kardiovaskulární nemoci farmakoterapie epidemiologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- obezita farmakoterapie epidemiologie MeSH
- prevalence MeSH
- průzkumy a dotazníky MeSH
- rizikové faktory MeSH
- senioři MeSH
- statiny terapeutické užití MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Česká republika MeSH
OBJECTIVE: The aim of this analysis was to analyze the presence of the most important cardiovascular (CV) risk factors and to discuss patterns of LDL cholesterol management in the population studied. METHODS: We enrolled 961 males, average age of 42.9 ± 4.7, and 851 females, average age of 51.2 ± 3.6. Data on personal, pharmacological and family history, and laboratory examinations were collected. Cardiovascular (CV) risk was calculated using the Systematic Coronary Risk Evaluation (SCORE) algorithm with modifications according to the guidelines. RESULTS: The distribution of CV risk in the observed cohort was as follows: 24% of the subjects had low, 51% moderate, 17% high and 8% very high risk. The percentage of patients who reached target values of LDL cholesterol was dramatically lower in the groups with very high (1%) and high (3%) risk than in the groups with moderate (14%) or low risk (59%). Dyslipidemia was newly identified in 20% of both sexes. Arterial hypertension was newly diagnosed in 8% of males and 5% of females, and type 2 diabetes mellitus was newly diagnosed in 3% of both the males and females. Dyslipidemia was present in 39% of males and 41% of females; arterial hypertension in 43% of males and 45% of females, and type 2 diabetes mellitus was diagnosed in 11% of the subjects of both sexes. 49% of males and 31% of females were overweight and 32% of both genders were obese. There were 36% of male smokers and 22% of female smokers. 48% of the participants were pharmacologically treated. Non-pharmacological treatment was recommended to 62% of male and to 65% of female participants. Pharmacological intervention was started in 53% of males and 51% of females. In both gender antihypertensive treatment with angiotensin-converting enzyme (ACE) inhibitors (29% of males and 27% of females) and lipid lowering therapy with a statin (28% of males, 27% of females) were the most commonly initiated treatments. In the subgroup of the 101 patients with LDL cholesterol levels > 5 mmol/L 56% were not treated with a statin. The analysis of relationship between the positive family history of any of the followed CV risks showed significant increases of the risk for arterial hypertension, type 2 diabetes mellitus and dyslipidemia. CONCLUSION: European guidelines suggest general screening for risk factors, including analysis of lipid profiles in the population of 40-year-old males and 50-year-old or postmenopausal women. Our study documents high prevalence and incidence of CV risk factors together with insufficient control of the risk factors in Czech patients of this age range. This finding suggests that preventive examinations should be undertaken earlier (e.g., in 30-year-old males and 40-year-old women). Exact timing of the preventive check-ups to yield the best cost-benefit ratio needs to be verified.
Department of Hygiene Institute of Clinical Experimental Medicine Prague Czech Republic
Internal Department Masaryk Hospital Usti nad Labem Czech Republic
Citace poskytuje Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20010303
- 003
- CZ-PrNML
- 005
- 20200721124455.0
- 007
- ta
- 008
- 200707s2020 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21101/cejph.a5730 $2 doi
- 035 __
- $a (PubMed)32592555
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Chmelík, Zdeněk $7 xx0224754 $u Third Department of Internal Medicine, Department of Endocrinology, Metabolism, First Medical Faculty, Charles University, General Faculty Hospital, Prague, Czech Republic
- 245 10
- $a Analysis of incidence and prevalence of cardiovascular risk factors and evaluation of their control in epidemiological survey in the Czech Republic / $c Z. Chmelík, M. Vaclová, V. Lánská, J. Laštůvka, M. Vrablík
- 504 __
- $a Literatura
- 520 9_
- $a OBJECTIVE: The aim of this analysis was to analyze the presence of the most important cardiovascular (CV) risk factors and to discuss patterns of LDL cholesterol management in the population studied. METHODS: We enrolled 961 males, average age of 42.9 ± 4.7, and 851 females, average age of 51.2 ± 3.6. Data on personal, pharmacological and family history, and laboratory examinations were collected. Cardiovascular (CV) risk was calculated using the Systematic Coronary Risk Evaluation (SCORE) algorithm with modifications according to the guidelines. RESULTS: The distribution of CV risk in the observed cohort was as follows: 24% of the subjects had low, 51% moderate, 17% high and 8% very high risk. The percentage of patients who reached target values of LDL cholesterol was dramatically lower in the groups with very high (1%) and high (3%) risk than in the groups with moderate (14%) or low risk (59%). Dyslipidemia was newly identified in 20% of both sexes. Arterial hypertension was newly diagnosed in 8% of males and 5% of females, and type 2 diabetes mellitus was newly diagnosed in 3% of both the males and females. Dyslipidemia was present in 39% of males and 41% of females; arterial hypertension in 43% of males and 45% of females, and type 2 diabetes mellitus was diagnosed in 11% of the subjects of both sexes. 49% of males and 31% of females were overweight and 32% of both genders were obese. There were 36% of male smokers and 22% of female smokers. 48% of the participants were pharmacologically treated. Non-pharmacological treatment was recommended to 62% of male and to 65% of female participants. Pharmacological intervention was started in 53% of males and 51% of females. In both gender antihypertensive treatment with angiotensin-converting enzyme (ACE) inhibitors (29% of males and 27% of females) and lipid lowering therapy with a statin (28% of males, 27% of females) were the most commonly initiated treatments. In the subgroup of the 101 patients with LDL cholesterol levels > 5 mmol/L 56% were not treated with a statin. The analysis of relationship between the positive family history of any of the followed CV risks showed significant increases of the risk for arterial hypertension, type 2 diabetes mellitus and dyslipidemia. CONCLUSION: European guidelines suggest general screening for risk factors, including analysis of lipid profiles in the population of 40-year-old males and 50-year-old or postmenopausal women. Our study documents high prevalence and incidence of CV risk factors together with insufficient control of the risk factors in Czech patients of this age range. This finding suggests that preventive examinations should be undertaken earlier (e.g., in 30-year-old males and 40-year-old women). Exact timing of the preventive check-ups to yield the best cost-benefit ratio needs to be verified.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a inhibitory ACE $x terapeutické užití $7 D000806
- 650 _2
- $a antihypertenziva $x terapeutické užití $7 D000959
- 650 _2
- $a kardiovaskulární nemoci $x farmakoterapie $x epidemiologie $7 D002318
- 650 _2
- $a diabetes mellitus 2. typu $x farmakoterapie $x epidemiologie $7 D003924
- 650 _2
- $a dyslipidemie $x farmakoterapie $x epidemiologie $7 D050171
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a statiny $x terapeutické užití $7 D019161
- 650 _2
- $a hypertenze $x farmakoterapie $x epidemiologie $7 D006973
- 650 _2
- $a incidence $7 D015994
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a obezita $x farmakoterapie $x epidemiologie $7 D009765
- 650 _2
- $a prevalence $7 D015995
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a průzkumy a dotazníky $7 D011795
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Vaclová, Martina $7 xx0160828 $u Third Department of Internal Medicine, Department of Endocrinology, Metabolism, First Medical Faculty, Charles University, General Faculty Hospital, Prague, Czech Republic
- 700 1_
- $a Lánská, Věra $7 xx0062305 $u Department of Hygiene, Institute of Clinical, Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Laštůvka, Jiří, $d 1968- $7 xx0242090 $u Third Department of Internal Medicine, Department of Endocrinology, Metabolism, First Medical Faculty, Charles University, General Faculty Hospital, Prague, Czech Republic; Internal Department, Masaryk Hospital, Usti nad Labem, Czech Republic
- 700 1_
- $a Vrablík, Michal, $d 1973- $7 xx0061419 $u Third Department of Internal Medicine, Department of Endocrinology, Metabolism, First Medical Faculty, Charles University, General Faculty Hospital, Prague, Czech Republic
- 773 0_
- $w MED00001083 $t Central European journal of public health $x 1210-7778 $g Roč. 28, č. 2 (2020), s. 114-119
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32592555 $y Pubmed
- 910 __
- $a ABA008 $b B 1829 $c 562 $y p $z 0
- 990 __
- $a 20200707 $b ABA008
- 991 __
- $a 20200710152052 $b ABA008
- 999 __
- $a ok $b bmc $g 1546298 $s 1100395
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 28 $c 2 $d 114-119 $i 1210-7778 $m Central European Journal of Public Health $n Cent. Eur. J. Public Health $x MED00001083
- LZP __
- $b NLK118 $a Pubmed-20200707